There is a metric in pharmaceutical patient services that doesn't get nearly enough attention in technology strategy discussions: time-to-fill. For a patient who has just been prescribed a specialty therapy, often for a serious or chronic condition, the number of days between that prescription and the first dose in their hands is not an abstract operational statistic. It is a real and material part of their treatment experience.
And yet, for most pharmaceutical companies, the hub services infrastructure that manages specialty patient onboarding, benefit investigation, prior authorization support, and pharmacy fulfillment coordination is one of the most underinvested areas of commercial technology. The opportunity is significant and largely untapped.
"Patient time-to-fill and refill performance are not just patient experience metrics. They are commercial metrics. For specialty therapies, they directly affect market share, brand reputation, and long-term revenue."
What Hub Services Actually Do
For pharmaceutical companies with specialty products, patient hub services are the operational infrastructure that bridges the gap between a prescription and fulfilled therapy. The complexity is substantial:
- Benefit investigation: Verifying insurance coverage, identifying prior authorization requirements, and determining patient cost-sharing obligations.
- Prior authorization management: Submitting, tracking, and appealing prior authorization requests across hundreds of payer and PBM combinations.
- Co-pay assistance: Enrolling patients in manufacturer co-pay programs and coordinating with pharmacy benefit managers.
- Specialty pharmacy coordination: Routing prescriptions to network specialty pharmacies, managing inventory availability, and tracking fulfillment status.
- Adherence support: Outreach programs to improve refill rates and support patients who are at risk of discontinuing therapy.
Each of these steps introduces potential delays and failure modes. A prior authorization that gets lost in a manual workflow. A benefit investigation that produces inconsistent results across cases. A refill reminder that isn't triggered because a patient record wasn't updated. Individually, each issue is small. Cumulatively, they produce the time-to-fill and adherence performance that patients experience, and that shows up in market share data.
The Technology Gap
Despite the commercial importance of hub services performance, many pharmaceutical companies are operating on hub platforms that were not designed for the complexity of modern specialty pharmacy. The core issues I've encountered most consistently are:
Fragmented data across the patient journey
Patient records that exist in separate systems for benefit investigation, prior authorization, co-pay enrollment, and pharmacy fulfillment, with limited integration between them, make it nearly impossible to understand the patient's actual status at any point in the journey. Case managers working from incomplete information make worse decisions and create more exceptions.
Manual workflows in high-volume processes
Prior authorization management is a volume problem at scale. For a major specialty brand, the hub may be processing thousands of PA requests per month across dozens of payer combinations. Manual review processes that made sense when volumes were lower become bottlenecks as the brand grows, and the delays compound.
Limited predictive capability
The most sophisticated hub operations I've seen use predictive analytics to identify patients at risk of non-adherence before they miss a refill, enabling proactive outreach rather than reactive response. Most hub operations are still primarily reactive, which means they're addressing adherence issues after they've already occurred.
For a specialty brand with 100,000 patients on therapy, a 5% improvement in 6-month adherence rates translates directly into meaningful revenue impact. Hub services technology investment is one of the highest-ROI commercial technology opportunities available to pharmaceutical companies, and it remains systematically underfunded relative to that return.
What a Modern Hub Platform Looks Like
The hub transformation I led integrated three architectural capabilities that had previously operated independently: the patient services platform, the specialty pharmacy network, and the brand's commercial data environment. The integration enabled a unified view of each patient's status across all stages of the access and fulfillment journey, from prescription received through first fill and ongoing adherence.
On top of that unified data layer, we built workflow automation that eliminated the most common manual bottlenecks in the PA management process, and predictive models that identified at-risk patients for proactive outreach. The results were measurable across all the metrics that matter: Rx fill rate improved, time-to-fill decreased, and refill performance across major brands improved meaningfully.
Why This Doesn't Get More Attention
Part of the reason hub services technology remains underinvested is organizational: hub operations typically sit in the market access or patient services function, which has less technology investment authority than commercial IT. The connections between hub performance metrics and commercial outcomes are real but are not always visible in the conversations where technology budgets are allocated.
The opportunity for technology leaders in pharmaceutical companies is to make those connections explicit: bringing hub performance data into commercial strategy discussions, to quantify the revenue impact of time-to-fill improvements, and to build the business case for hub platform investment in terms that commercial leadership can immediately engage with.
The patients who are waiting for their therapy, and the commercial teams who are watching their market share numbers, are counting on someone to make that case.